Simon Robert Eade

Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom.

Johnson & Johnson Innovation Ltd is a private equity subsidiary of Johnson & Johnson Innovation - JJDC, Inc. founded in 2000. The firm is headquartered in Buckinghamshire, United Kingdom.

Johnson & Johnson Foundation Scotland was founded in 2007. The British company's description is unrelated to their actual business.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

The White Ribbon Alliance for Safe Motherhood operates as a non-profit organization. It aims to decrease maternal and newborn death globally. The company is headquartered in Washington, DC.

Theramex HQ UK Ltd. operates as a international pharmaceutical company that provides healthcare solutions for women. The company was founded in 1970 and is headquartered in London, the United Kingdom.

Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain.

Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education.